Patent Claims

1. Compounds of the formula I

5 10 in which R^1 , R^2 are each, independently of one another, H, =O, Hal, A, ethynyl, OR³, N(R³)₂, NO₂, CN, N₃, COOR³, CON(R³)₂, $-[C(R^4)_2]_n$ -Ar, $-[C(R^4)_2]_n$ -Het, $-[C(R^4)_2]_n$ -cycloalkyl, $-OCOR^3$, 15 -OCON(R3)2, NR3COA or NR3SO2A, R¹ and R² together are alternatively a bicyclically or spirocyclically bonded 3- to 7-membered carbocyclic or heterocyclic ring having from 0 to 3 N, O and/or S atoms, 20 is H. A. H-C≡C-CH₂-, CH₃-C≡C-CH₂-, -CH₂-CH(OH)- R^3 CH2OH, -CH2-CH(OH)-CH2NH2, -CH2-CH(OH)-CH2Het', $-[C(R^4)_2]_n$ -Ar', $-[C(R^4)_2]_n$ -Het', $-[C(R^4)_2]_n$ -cycloalkyl, $-[C(R^4)_2]_n$ -COOA or $-[C(R^4)_2]_nN(R^4)_2$, R⁴ is H or A, 25 is N. CR³ or an sp²-hybridised carbon atom, W together with W is a 3- to 7-membered saturated carbo-Ε cyclic or heterocyclic ring having from 0 to 3 N, from 0 to 2 O and/or from 0 to 2 S atoms, 30 which may contain a double bond, is a monocyclic or bicyclic, aromatic carbocyclic or hetero-D cyclic ring having from 0 to 4 N, O and/or S atoms which is unsubstituted or monosubstituted or polysubstituted by 35 Hal, A, OR³, N(R³)₂, NO₂, CN, COOR³ or CON(R³)₂,

	G	is $-[C(R^4)_2]_{n^-}$, $-[C(R^4)_2]_nNR^3$ -, $-[C(R^4)_2]_nO$ -, $-[C(R^4)_2]_nS$ - or $-[C(R^4)=C(R^4)]_{n^-}$,
	X	is $-[C(R^4)_2]_nCONR^3[C(R^4)_2]_{n^-}$, $-[C(R^4)_2]_nNR^3CO[C(R^4)_2]_{n^-}$,
5		$-[C(R^4)_2]_nNR^3[C(R^4)_2]_{n^-}, -[C(R^4)_2]_nO[C(R^4)_2]_{n^-},$
		$-[C(R^4)_2]_nCO[C(R^4)_2]_{n^-}$ or $-[C(R^4)_2]_nCOO[C(R^4)_2]_{n^-}$,
	Y	is alkylene, cycloalkylene, Het-diyl or Ar-diyl,
	Т	is a monocyclic or bicyclic, saturated or unsaturated carbo-
		cyclic or heterocyclic ring having from 0 to 4 N, O and/or S
10		atoms which is monosubstituted or disubstituted by =O,
		$=S$, $=NR^3$, $=N-CN$, $=N-NO_2$, $=NOR^3$, $=NCOR^3$
		or =NOCOR ³ and may furthermore be monosubstituted,
		disubstituted or trisubstituted by R^3 , Hal, A, $-[C(R^4)_2]_n$ -Ar, -
15		$[C(R^4)_2]_n$ -Het, $-[C(R^4)_2]_n$ -cycloalkyl, OR^3 , $N(R^3)_2$, NO_2 , CN ,
		$COOR^3$, $CON(R^3)_2$, NR^3COA , $NR^3CON(R^3)_2$, NR^3SO_2A ,
		COR³, SO₂NR³ and/or S(O) _n A,
	Α	is unbranched or branched alkyl having 1-10 carbon atoms
	٠	in which one or two CH ₂ groups may be replaced by O or S
20 .		atoms and/or by -CH=CH- groups and/or in addition 1-7 H
		atoms may be replaced by F,
	Ar	is phenyl, naphthyl or biphenyl, each of which is unsubsti-
		tuted or monosubstituted, disubstituted or trisubstituted by
25		Hal, A, OR ³ , N(R ³) ₂ , NO ₂ , CN, COOR ³ , CON(R ³) ₂ ,
•		NR^3COA , $NR^3CON(R^3)_2$, NR^3SO_2A , COR^3 , $SO_2N(R^3)_2$,
		$S(O)_nA$, $-[C(R^4)_2]_n-COOR^3$ or $-O[C(R^4)_2]_o-COOR^3$,
	Ar'	is phenyl, naphthyl or biphenyl, each of which is unsubsti-
30		tuted or monosubstituted, disubstituted or trisubstituted by
50		Hal, A, OR^4 , $N(R^4)_2$, NO_2 , CN , $COOR^4$, $CON(R^4)_2$,
•		NR^4COA , $NR^4CON(R^4)_2$, NR^4SO_2A , COR^4 , $SO_2N(R^4)_2$,
		$S(O)_{n}A$, $-[C(R^{4})_{2}]_{n}$ - $COOR^{4}$ or $-O[C(R^{4})_{2}]_{o}$ - $COOR^{4}$,
	Het	is a monocyclic or bicyclic, saturated, unsaturated or aro-
35		matic heterocyclic ring having from 1 to 4 N, O and/or S
		atoms which may be unsubstituted or monosubstituted,

disubstituted or trisubstituted by Hal, A, -[C(R⁴)₂]_n-Ar, $-[C(R^4)_2]_n$ -Het', $-[C(R^4)_2]_n$ -cycloalkyl, OR^3 , $N(R^3)_2$, $NR^3CON(R^3)_2$, NO_2 , CN, $-[C(R^4)_2]_n$ - $COOR^3$, $-[C(R^4)_2]_n$ -CON(R³)₂, NR³COA, NR³SO₂A, COR³, SO₂NR³, 5 S(O)_mA and/or carbonyl oxygen, is a monocyclic or bicyclic, saturated, unsaturated or aro-Het' matic heterocyclic ring having from 1 to 4 N, O and/or S atoms which may be unsubstituted or monosubstituted or 10 disubstituted by carbonyl oxygen, =S, =N(R⁴)₂, Hal, A, OR⁴, N(R⁴)₂, NO₂, CN, COOR⁴, CON(R⁴)₂, NR⁴COA, NR⁴CON(R⁴)₂, NR⁴SO₂A, COR⁴, SO₂NR⁴ and/or S(O)_nA, Hal is F, Cl, Br or I, is 0, 1 or 2, n 15 is 1, 2 or 3, and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

- 20 2. Compounds according to Claim 1, in which
 - D is a monocyclic or bicyclic, aromatic carbocyclic or heterocyclic ring having from 0 to 4 N, O and/or S atoms which is unsubstituted or monosubstituted or disubstituted by Hal, and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.
 - 3. Compounds according to Claim 1 or 2, in which
- D is phenyl, pyridyl, thienyl, furyl or imidazolyl, each of which is monosubstituted or disubstituted by Hal, and pharmaceutically usable derivatives, solvates, salts and stereo-isomers thereof, including mixtures thereof in all ratios.
- 4. Compounds according to one or more of Claims 1-3,in which

R^1 , R^2	are each, independently of one another, H, =O, COOR ³ ,
	OH, OA, NH ₂ , alkyl having 1, 2, 3, 4, 5 or 6 carbon
	atoms, N₃, ethynyl, vinyl, allyloxy, NHCOA, NHSO₂A,
	OCH₂COOA or OCH₂COOH,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

- Compounds according to one or more of Claims 1-4,
 in which
 - G is $(CH_2)_n$, $(CH_2)_nNH_-$, -CH=CH- or -CH=CH-CH=CH-, and pharmaceutically usable derivatives, solvates, salts and stereo-isomers thereof, including mixtures thereof in all ratios.

15

20

10

- 6. Compounds according to one or more of Claims 1-5, in which
 - X is $-[C(R^4)_2]_nCONR^3[C(R^4)_2]_n$ -, and pharmaceutically usable derivatives, solvates, salts and stereo-isomers thereof, including mixtures thereof in all ratios.
- 7. Compounds according to one or more of Claims 1-6, in which

25 X is -CONH- or -CON(CH₂COOA)-, and pharmaceutically usable derivatives,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

- 8. Compounds according to one or more of Claims 1-7, in which
 - Y is cycloalkylene, Het-diyl or Ar-diyl, and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

35

9. Compounds according to Claims 1-8,

10

15

20

25

30

35

in		

- Y is pyridinediyl, piperidinediyl, cyclohexylene, or phenylene which is unsubstituted or monosubstituted or disubstituted by A, OA, CI, F, COOCH₃, COOH, phenoxy or aminocarbonyl, and pharmaceutically usable derivatives, solvates, salts and stereo-isomers thereof, including mixtures thereof in all ratios.
- Compounds according to one or more of Claims 1-9,
 in which
 - T is a monocyclic, saturated or unsaturated heterocyclic ring having 1 to 2 N and/or O atoms which is monosubstituted or disubstituted by =O, =S or =NH and may be monosubstituted or disubstituted by Hal, A and/or OA,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

- Compounds according to one or more of Claims 1-10,
 in which
 - is piperidin-1-yl, pyrrolidin-1-yl, pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl, 2-azabicyclo[2.2.2]octan-2-yl, imidazolidinyl, thiazolyl or 1,4-oxazepanyl, each of which is monosubstituted or disubstituted by =O or =NH and where the radicals may also be monosubstituted or disubstituted by Hal, A and/or OA,
 - and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.
 - Compounds according to one or more of Claims 1-11, in which

is phenyl which is unsubstituted or monosubstituted or disub-Ar stituted by Hal, A, OA, SO₂A, COOR², SO₂NH₂, CN, COOA, COOH or phenoxy,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

Compounds according to one or more of Claims 1-12, 13. in which

	in which	
10	Ď	is a monocyclic or bicyclic, aromatic carbocyclic or
		heterocyclic ring having from 0 to 4 N, O and/or S atoms
		which is unsubstituted or monosubstituted or disubsti-
		tuted by Hal,
4.5	R^1 , R^2	are each, independently of one another, H, =O, COOR ³ ,
15		OH, OA, NH_2 , alkyl having 1, 2, 3, 4, 5 or 6 carbon
		atoms, N₃, ethynyl, vinyl, allyloxy, NHCOA, NHSO₂A,
	•	OCH₂COOA or OCH₂COOH,
	R ¹ and R ²	together are alternatively a spirocyclically bonded 3- to
20		6-membered carbocyclic ring,
•	R^3	is H, A, phenyl, benzyl or [C(R ⁴) ₂] _n COOA,
	R ⁴	is H or A,
	W	is N, CR ³ or an sp ² -hybridised carbon atom,
25	E	together with W is a 3- to 7-membered saturated carbo-
		cyclic or heterocyclic ring having from 0 to 3 N, from 0 to
		2 O and/or from 0 to 2 S atoms,
		which may contain a double bond,
30	G	is $(CH_2)_n$, $(CH_2)_nNH$, $-CH=CH$ or $-CH=CH$ CH=CH,
	X	is $-[C(R^4)_2]_nCONR^3[C(R^4)_2]_n$ -,
	Υ	is cycloalkylene, Het-diyl or Ar-diyl,
	Ar	is phenyl which is unsubstituted or monosubstituted or
		disubstituted by Hal, A, OA, SO ₂ A, COOR ² , SO ₂ NH ₂ ,
35		CN. COOA, COOH or phenoxy,

CN, COOA, COOH or phenoxy,

•			
_		Т	is a monocyclic, saturated or unsaturated heterocyclic ring having 1 to 2 N and/or O atoms which is monosubstituted or disubstituted by =O, =S or =NH and may be monosubstituted or disubstituted by Hal, A and/or OA,
5	-	Α	is unbranched or branched alkyl having 1-10 carbon atoms and in which 1-7 H atoms may be replaced by F,
		Hal	is F, Cl, Br or I,
		n	is 0, 1 or 2,
10		and pharma	ceutically usable derivatives, solvates, salts and stereo-
		isomers the	reof, including mixtures thereof in all ratios.
•	14.	Compounds	according to one or more of Claims 1-13,
15	•	in which	
. •		D .	is phenyl, pyridyl, thienyl, furyl or imidazolyl, each of
			which is monosubstituted or disubstituted by Hal,
		R^1 , R^2	are each, independently of one another, H, =O, COOR ³ ,
		•.	OH, OA, NH ₂ , alkyl having 1, 2, 3, 4, 5 or 6 carbon
20			atoms, N₃, ethynyl, vinyl, allyloxy, NHCOA, NHSO₂A,
			OCH₂COOA or OCH₂COOH,
		R^1 and R^2	together are alternatively a spirocyclically bonded 3- to
			6-membered carbocyclic ring,
25		R^3	is H, A or CH₂COOA,
		R⁴ .	is H or A,
		W	is N, CR ³ or an sp ² -hybridised carbon atom,
		Ε	together with W is a 3- to 7-membered saturated carbo-
. 30			cyclic or heterocyclic ring having from 0 to 3 N, from 0 to
			2 O and/or from 0 to 2 S atoms,
			which may contain a double bond,
		G	is $(CH_2)_n$, $(CH_2)_nNH$, $-CH=CH$ or $-CH=CHCH=CH$,
2.5		X	is -CONH- or -CON(CH₂COOA)-,
35		Y	is pyridinediyl, piperidinediyl, cyclohexylene, or
			phenylene which is unsubstituted or monosubstituted or

			disubstituted by A, OA, CI, F, COOCH ₃ , COOH,
			phenoxy or aminocarbonyl,
		Т	is piperidin-1-yl, pyrrolidin-1-yl, pyridin-1-yl, morpholin-4-
,			yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, pyridazin-2-yl,
5			pyrazin-1-yl, azepan-1-yl, 2-azabicyclo[2.2.2]octan-2-yl,
			imidazolidinyl, thiazolyl or 1,4-oxazepanyl, each of which
			is monosubstituted or disubstituted by =O or =NH and
			where the radicals may also be monosubstituted or
10			disubstituted by Hal, A and/or OA,
		Α	is unbranched or branched alkyl having 1-10 carbon
			atoms and in which 1-7 H atoms may be replaced by F,
	٠	Hal	is F, Cl, Br or I,
15		n	is 0, 1 or 2,
		and pharma	ceutically usable derivatives, solvates, salts and stereo-
		isomers the	reof, including mixtures thereof in all ratios.
20	15.	Compounds	s according to one or more of Claims 1-14,
20	•	in which	
		D .	
			is phenyl, pyridyl or thienyl, each of which is
			monosubstituted or disubstituted by Hal,
		R ¹	
25		R ¹	monosubstituted or disubstituted by Hal,
25		R ¹	monosubstituted or disubstituted by Hal, is H, =O, COOR ³ , OH, OA, NH ₂ , alkyl having 1, 2, 3, 4,
25		R^1 R^2	monosubstituted or disubstituted by Hal, is H, =O, COOR ³ , OH, OA, NH ₂ , alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N ₃ , ethynyl, vinyl, allyloxy,
25		•	monosubstituted or disubstituted by Hal, is H, =O, COOR ³ , OH, OA, NH ₂ , alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N ₃ , ethynyl, vinyl, allyloxy, -OCOR ³ , NHCOA or NHSO ₂ A,
25 30		•	monosubstituted or disubstituted by Hal, is H, =O, COOR ³ , OH, OA, NH ₂ , alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N ₃ , ethynyl, vinyl, allyloxy, -OCOR ³ , NHCOA or NHSO ₂ A, is H, =O, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 car-
		R^2 R^1 and R^2	monosubstituted or disubstituted by Hal, is H, =O, COOR ³ , OH, OA, NH ₂ , alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N ₃ , ethynyl, vinyl, allyloxy, -OCOR ³ , NHCOA or NHSO ₂ A, is H, =O, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,
		R^2 R^1 and R^2 R^3	monosubstituted or disubstituted by Hal, is H, =O, COOR ³ , OH, OA, NH ₂ , alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N ₃ , ethynyl, vinyl, allyloxy, -OCOR ³ , NHCOA or NHSO ₂ A, is H, =O, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, together are alternatively a spirocyclically bonded 3- to
		R^2 R^1 and R^2	monosubstituted or disubstituted by Hal, is H, =O, COOR ³ , OH, OA, NH ₂ , alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N ₃ , ethynyl, vinyl, allyloxy, -OCOR ³ , NHCOA or NHSO ₂ A, is H, =O, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, together are alternatively a spirocyclically bonded 3- to 6-membered carbocyclic ring,

		$\binom{E}{W}$	is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-
5			3,4- or 3,5-diyl, thiazolidine-3,4-diyl, 2,5-dihydro-1 <i>H</i> -pyrrole-1,5-diyl, 1,3-dioxolane-4,5-diyl, 1,3-oxazinane-
			3,4-diyl, piperazine-1,4-diyl, tetrahydrofuran-3,4-diyl or azetidine-1,2-diyl,
		G	is $(CH_2)_n$ or $(CH_2)_nNH$,
10		X	is CONH,
. •		Y	is 1,3- or 1,4-phenylene which is unsubstituted or mono-
-			substituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, CI or F,
15		Т	is piperidin-1-yl, pyrrolidin-1-yl, 1 <i>H</i> -pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, 2 <i>H</i> -pyri-
			dazin-2-yl, pyrazin-1-yl, azepan-1-yl or 2-azabicyclo-
			[2.2.2]octan-2-yl, each of which is monosubstituted or
			disubstituted by carbonyl oxygen,
20		Α	is unbranched or branched alkyl having 1-10 carbon
	•		atoms and in which 1-7 H atoms may be replaced by F,
		Hal	is F, Cl, Br or I,
		n	is 0, 1 or 2;
25		and pharma	ceutically usable derivatives, solvates, salts and stereo-
		isomers the	reof, including mixtures thereof in all ratios.
	16.	Compounds	according to one or more of Claims 1-15,
30		in which	
00		D .	is phenyl, pyridyl or thienyl, each of which is
			monosubstituted or disubstituted by Hal,
		R ¹	is H, =O, COOR 3 , OH, OA, NH $_2$, alkyl having 1, 2, 3, 4,
			5 or 6 carbon atoms, N ₃ , ethynyl, vinyl, allyloxy,
35			-OCOR ³ , NHCOA or NHSO₂A,

		R ²	is H, =O, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,
		R ¹ and R ²	together are alternatively a spirocyclically bonded 3- to 6-membered carbocyclic ring,
5		R^3	is H or A,
		R ⁴	is H or A,
10		(E)	is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-
10		••	3,4- or 3,5-diyl, thiazolidine-3,4-diyl, 2,5-dihydro-1 <i>H</i> -
			pyrrole-1,5-diyl, 1,3-dioxolane-4,5-diyl, 1,3-oxazinane-
-			3,4-diyl, piperazine-1,4-diyl, tetrahydrofuran-3,4-diyl or azetidine-1,2-diyl,
15		G.	is $(CH_2)_n$ or $(CH_2)_nNH$ -,
		X	is CONH,
		Υ	is 1,3- or 1,4-phenylene which is unsubstituted or mono-
			substituted or disubstituted by methyl, trifluoromethyl,
20	•		ethyl, propyl, Cl or F,
		T ·	is morpholin-4-yl which is monosubstituted or disubsti-
			tuted by carbonyl oxygen,
		Α	is unbranched or branched alkyl having 1-10 carbon
25			atoms and in which 1-7 H atoms may be replaced by F,
		Hal	is F, Cl, Br or I,
		n	is 0, 1 or 2;
·		and pharma	ceutically usable derivatives, solvates, salts and stereo-
30		isomers the	reof, including mixtures thereof in all ratios.
	17.	Compounds	s according to one or more of Claims 1-16,
	17.	in which	s according to one or more or claims 1 10,
		•	$C(R^4)_2]_nCONR^3[C(R^4)_2]_{n^-}$ or $-[C(R^4)_2]_nCO[C(R^4)_2]_{n^-}$,
35		_	aceutically usable derivatives, solvates, salts and stereo-
		•	reof, including mixtures thereof in all ratios.
•		.555.5 410	· = - · · · · · · · · · · · · · · · · ·

10

15

20

25

30

35

18.	Compounds according to one or more of Claims 1-17,
	in which

X is CONH or COCH₂, and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

19. Compounds according to one or more of Claims 1-18, in which

D is phenyl, pyridyl or thienyl, each of which is monosubstituted or disubstituted by Hal,

R¹ is H, =O, COOR³, OH, OA, NH₂, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N₃, ethynyl, vinyl, allyloxy,

-OCOR³, NHCOA or NHSO₂A,

R² is H, =O, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

R¹ and R² together are alternatively a spirocyclically bonded 3- to 6-membered carbocyclic ring,

R³ is H or A,

R⁴ is H or A,

is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-

3,4- or 3,5-diyl, thiazolidine-3,4-diyl, 2,5-dihydro-1*H*-pyrrole-1,5-diyl, 1,3-dioxolane-4,5-diyl, 1,3-oxazinane-3,4-diyl, piperazine-1,4-diyl, tetrahydrofuran-3,4-diyl or azetidine-1,2-diyl,

G is $(CH_2)_n$ or $(CH_2)_nNH_{-}$,

X is CONH or COCH₂,

γ is 1,3- or 1,4-phenylene which is unsubstituted or monosubstituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F,

		•
•	Т	is morpholin-4-yl which is monosubstituted or disubsti-
		tuted by carbonyl oxygen,
-	Α	is unbranched or branched alkyl having 1-10 carbon
5		atoms and in which 1-7 H atoms may be replaced by F,
J	Hal	is F, Cl, Br or I,
	n	is 0, 1 or 2,
	and pharma	aceutically usable derivatives, solvates, salts and stereo-
	isomers the	ereof, including mixtures thereof in all ratios.
10		
2	0. Compound	s according to one or more of Claims 1-19,
	in which	
	D	is phenyl, pyridyl or thienyl, each of which is
15		monosubstituted or disubstituted by Hal,
	R^1	is H, =O, COOR ³ , OH, OA, NH ₂ , alkyl having 1, 2, 3, 4,
		5 or 6 carbon atoms, N ₃ , ethynyl, vinyl, allyloxy,
		-OCOR ³ , NHCOA, NHSO₂A, H-C≡C-CH₂-,
		CH ₃ -C≡C-CH ₂ -O-, -O-CH ₂ -CH(OH)-CH ₂ OH,
20		-O-CH ₂ -CH(OH)-CH ₂ NH ₂ or -O-CH ₂ -CH(OH)-CH ₂ Het',
	R^2	is H, =O, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 car-
		bon atoms,
	R ¹ and R ²	together are alternatively a spirocyclically bonded 3- to
25		6-membered carbocyclic ring,
	R^3	is H or A,
	R ⁴	is H or A,
	/ E \	
30		is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-
00	\w'	•
		3,4- or 3,5-diyl, thiazolidine-3,4-diyl, 2,5-dihydro-1 <i>H</i> -
		pyrrole-1,5-diyl, 1,3-dioxolane-4,5-diyl, 1,3-oxazinane-
·		3,4-diyl, piperazine-1,4-diyl, tetrahydrofuran-3,4-diyl or
35		azetidine-1,2-diyl,
•	G	is $(CH_2)_n$ or $(CH_2)_nNH_{-}$,

		X Y	is CONH or $COCH_2$, is 1,3- or 1,4-phenylene which is unsubstituted or mono-
_			substituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F,
5		Т	is morpholin-4-yl which is monosubstituted or disubstituted by carbonyl oxygen,
		Het'	is a saturated 3-6-membered heterocyclic ring having
10			from 1 to 3 N and/or O atoms, which may be unsubstituted or monosubstituted or disubstituted by carbonyl
			oxygen, Hal, A, OH, NH ₂ , NO ₂ , CN, COOA or CONH ₂ ,
		Α	is unbranched or branched alkyl having 1-10 carbon
			atoms and in which 1-7 H atoms may be replaced by F,
15		Hal	is F, Cl, Br or I,
		n	is 0, 1 or 2,
		and pharma	ceutically usable derivatives, solvates, salts and stereo-
		isomers the	reof, including mixtures thereof in all ratios.
20	21.	Compounds	according to one or more of Claims 1-20,
		D	is phenyl, pyridyl or thienyl, each of which is mono- substituted or disubstituted by Hal,
25		R^1	is ethynyl, vinyl, allyloxy, CH₃-C≡C-CH₂-O-,
20		, , , , , , , , , , , , , , , , , , ,	-O-CH ₂ -CH(OH)-CH ₂ OH, -O-CH ₂ -CH(OH)-CH ₂ NH ₂ or
			-O-CH ₂ -CH(OH)-CH ₂ Het',
		R^2	is H or OH,
		R^1 and R^2	together are alternatively a spirocyclically bonded 3- to
30		it allu it	6-membered carbocyclic ring,
		R^3	is H or A,
		R ⁴	is H or A,
		18	

		(E) .	is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-
5			3,4- or 3,5-diyl, thiazolidine-3,4-diyl, 2,5-dihydro-1 <i>H</i> -pyrrole-1,5-diyl, 1,3-dioxolane-4,5-diyl, 1,3-oxazinane-3,4-diyl, piperazine-1,4-diyl, tetrahydrofuran-3,4-diyl or
<i>:</i>			azetidine-1,2-diyl,
		G	is $(CH_2)_n$ or $(CH_2)_nNH_{-}$,
10		X	is CONH, CO, COO or COCH ₂ ,
		Y	is 1,3- or 1,4-phenylene which is unsubstituted or mono-
		• •	substituted or disubstituted by methyl, trifluoromethyl,
		•	ethyl, propyl, Cl or F,
15		$_{r}$ T	is piperidin-1-yl, pyrrolidin-1-yl, 1 <i>H</i> -pyridin-1-yl, mor-
15	•	•	pholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, 2 <i>H</i> -pyri-
			dazin-2-yl, pyrazin-1-yl, azepan-1-yl or 2-azabicyclo-
	•		[2.2.2]octan-2-yl, each of which is monosubstituted or
			disubstituted by carbonyl oxygen or OA,
20		Het'	is a saturated 3-6-membered heterocyclic ring having
	-		from 1 to 3 N and/or O atoms, which may be unsubstitu-
			ted or monosubstituted or disubstituted by carbonyl
			oxygen, Hal, A, OH, NH ₂ , NO ₂ , CN, COOA or CONH ₂ ,
25		Α	is unbranched or branched alkyl having 1-10 carbon
			atoms and in which 1-7 H atoms may be replaced by F,
	•	Hal	is F, Cl, Br or I,
		n ·	is 0, 1 or 2,
		and pharma	aceutically usable derivatives, solvates, salts and stereo-
30		isomers the	reof, including mixtures thereof in all ratios.
	22.	Compound	s according to one or more of Claims 1-21,
		in which	
35		D	is phenyl, pyridyl, thienyl, furyl or imidazolyl, each of
			which is monosubstituted or disubstituted by Hal,

	R ¹	is H, =O, COOR ³ , OH, OA, NH ₂ , alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N ₃ , ethynyl, vinyl, allyloxy,
•		NHCOA, NHSO ₂ A, OCH ₂ COOA or OCH ₂ COOH,
5	R ²	is H, =O, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,
	R ¹ and R ²	together are alternatively a spirocyclically bonded 3- to
		6-membered carbocyclic ring,
	R^3	is H or A,
10	R ⁴	is H or A,
	(E)	is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-
		3,4- or 3,5-diyl, thiazolidine-3,4-diyl, 2,5-dihydro-1H-
15		pyrrole-1,5-diyl, 1,3-dioxolane-4,5-diyl, 1,3-oxazinane-
		3,4-diyl, piperazine-1,4-diyl, tetrahydrofuran-3,4-diyl or
		azetidine-1,2-diyl,
	G	is $(CH_2)_n$, $(CH_2)_nNH$, -CH=CH- or -CH=CH-CH=CH-,
20 .	Χ	is CONH, COCH₂ or -CON(CH₂COOA)-,
	Υ	is pyridinediyl, piperidinediyl, cyclohexylene, or
		phenylene which is unsubstituted or monosubstituted or
		disubstituted by A, OA, Cl, F, COOCH ₃ , COOH,
25		phenoxy or aminocarbonyl,
	Т	is morpholin-4-yl which is monosubstituted or disubstitu-
		ted by carbonyl oxygen,
	Α	is unbranched or branched alkyl having 1-10 carbon
20	•	atoms and in which 1-7 H atoms may be replaced by F,
30	Hal	is F, Cl, Br or I,
	n	is 0, 1 or 2,
	and pharma	aceutically usable derivatives, solvates, salts and stereo-
	isomers the	ereof, including mixtures thereof in all ratios.
35		

23.	Compounds according to Claim 1, selected from the group consisting
	of

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

10

1-N-[(4-chlorophenyl)]-2-N-{[3-fluoro-4-(3-oxomorpholin-4-yl)-phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)-phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

15

1-N-[(4-chlorophenyl)]-2-N-{[3-trifluoromethyl-4-(3-oxomorpholin-4-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]}-(R)-piperidine-1,2-dicarboxamide,

 $1-N-[(4-chlorophenyl)]-2-N-\{[4-(2-oxo-2\emph{H}-pyridin-1-yl)phenyl]\}-(R)-pyrrolidine-1,2-dicarboxamide,$

20

1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,

1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(R)-2.5-dihydropyrrole-1,2-dicarboxamide,

25

N-[4-(3-oxomorpholin-4-yl)phenyl]-(R)-1-(5-chlorothiophene-2-carbonyl)pyrrolidine-2-carboxamide,

N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-(R)-1-(5-chloro-thiophene-2-carbonyl)pyrrolidine-2-carboxamide,

30

3-N-[(4-chlorophenyl)]-4-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(R)-oxazolidine-3,4-dicarboxamide,

3-N-[(4-chlorophenyl)]-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)-phenyl]}-(R)-oxazolidine-3,4-dicarboxamide,

35

3-N-[(4-chlorophenyl)]-4-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,

	3-N-[(4-chlorophenyl)-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)-
	phenyl]}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,
	$3-N-[(4-chlorophenyl)]-4-N-{[4-(2-oxo-2H-pyridin-1-yl)phenyl]}-$
_	(R)-oxazolidine-3,4-dicarboxamide,
5	3-N-[(4-chlorophenyl)]-4-N-{[4-(2-oxo-2H-pyridin-1-yl)phenyl]}-
-	(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,
	3-N-[(4-chlorophenyl)]-4-N-{[3-fluoro-4-(3-oxomorpholin-4-yl)-
	phenyl]}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,
10	3-N-[(4-chlorophenyl)]-4-N-{[3-chloro-4-(3-oxomorpholin-4-yl)-
	phenyl]}-(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,
	3-N-[(4-chlorophenyl)]-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)-
	phenyl]}-(4R,5R)-5-methyloxazolidine-3,4-dicarboxamide,
15	3-N-[(4-chlorophenyl)]-4-N-{[4-(2-oxo-2H-pyrazin-1-yl)phenyl]}-
•	(4R,5S)-5-methyloxazolidine-3,4-dicarboxamide,
	3-N-[(4-chlorophenyl)]-4-N-{[4-(2-oxo-2H-pyrazin-1-yl)phenyl]}-
	(R)-oxazolidine-3,4-dicarboxamide,
20	3-N-[(4-chlorophenyl)]-4-N-{[3-chloro-4-(2-oxo-2H-pyridin-1-
20	yl)phenyl]}-(R)-oxazolidine-3,4-dicarboxamide,
	3-N-[(4-chlorophenyl)]-4-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
	(S)-thiazolidine-3,4-dicarboxamide,
	3-N-[(4-chlorophenyl)]-4-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
25	(S)-1,1-dioxo-1λ ⁶ -thiazolidine-3,4-dicarboxamide,
	3-N-[(4-chlorophenyl)]-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)-
	phenyl]}-(S)-thiazolidine-3,4-dicarboxamide,
	3-N-[(4-chlorophenyl)]-4-N-{[3-methyl-4-(3-oxomorpholin-4-yl)-
30	phenyl]}-(S)-1,1-dioxo-1λ ⁶ -thiazolidine-3,4-dicarboxamide,
	3-N-[(4-chlorophenyl)]-4-N-{[4-(2-oxo-2H-pyridin-1-yl)phenyl]}-
	(R)-thiazolidine-3,4-dicarboxamide,
	N-[4-(3-oxomorpholin-4-yl)phenyl]-3-(5-chlorothiophene-2-
35	carbonyl)oxazolidine-5-carboxamide,
33	N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-3-(5-chlorothio-
	phene-2-carbonyl)oxazolidine-5-carboxamide,

	N-[4-(2-oxo-2H-pyridin-1-yl)phenyl]-3-(5-chlorothiophene-2-
	carbonyl)oxazolidine-5-carboxamide,
	1-N-[(5-chloropyridin-2-yl)]-2-N-{[4-(2-oxo-2 <i>H</i> -pyridin-1-yl)-
_	phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
5	1-N-[(5-chloropyridin-2-yl)]-2-N-{[4-(3-oxomorpholin-4-yl)-
	phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
	1-N-[(5-chloropyridin-2-yl)]-2-N-{[4-(2-oxo-2H-pyrazin-1-yl)-
	phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
10	1-N-[(5-chloropyridin-2-yl)]-2-N-{[3-fluoro-4-(2-oxo-2 <i>H</i> -pyridin-1-
ü	yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
	1-N-[(5-chloropyridin-2-yl)]-2-N-{[4-(2-oxo-2 <i>H</i> -pyridin-1-yl)-
	phenyl]}-(R)-4,4-dimethoxypyrrolidine-1,2-dicarboxamide,
15	1-N-[(5-chloropyridin-2-yl)]-2-N-{[4-(3-oxomorpholin-4-yl)-
	phenyl]}-(R)-4,4-dimethoxypyrrolidine-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-2H-pyridin-1-yl)phenyl]}-
·	(R)-4,4-dimethoxypyrrolidine-1,2-dicarboxamide,
,	1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
20	(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)-
	phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-2 <i>H</i> -pyridin-1-yl)phenyl]}-
25	(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)-
	phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
30 35	1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxopyrazin-1-yl)phenyl]}-
	(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[3-fluoro-4-(2-oxo-2 <i>H</i> -pyridin-1-yl)-
	phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[3-fluoro-4-(3-oxomorpholin-4-yl)-
	phenyl]}-(2R,3R)-3-hydroxypyrrolidine-1,2-dicarboxamide,

	1-N-[(4-chlorophenyl)]-2-N-{[3-fluoro-4-(3-oxomorpholin-4-yl)-
	phenyl]}-(2R,3S)-3-hydroxypyrrolidine-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
	(2R,4S)-4-hydroxypyrrolidine-1,2-dicarboxamide,
5	1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
	(2S,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
•	3,4-dihydroxypyrrolidine-1,2-dicarboxamide,
10	1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
	(2R,4S)-4-azidopyrrolidine-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
	(2R,4S)-4-aminopyrrolidine-1,2-dicarboxamide,
15	1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
10	(2R,4R)-4-azidopyrrolidine-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
	(2R,4R)-4-aminopyrrolidine-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
20	(2R,4S)-4-acetaminopyrrolidine-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
	(2R,4R)-4-acetaminopyrrolidine-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
25	(2R,4S)-4-methylsulfonylaminopyrrolidine-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
	(2R,4R)-4-methylsulfonylaminopyrrolidine-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
30	(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
	(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
25	(2R,4R)-4-propoxypyrrolidine-1,2-dicarboxamide,
35	1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
•	(2R,4R)-4-allyloxypyrrolidine-1,2-dicarboxamide,

	(3R,5R)-1-(4-chlorophenylcarbamoyl)-5-[4-(3-oxomorpholin-4-yl)phenylcarbamoyl]pyrrolidin-3-yl isobutyrate,
	(3R,5R)-1-(4-chlorophenylcarbamoyl)-5-[4-(3-oxomorpholin-
	4-yl)phenylcarbamoyl]pyrrolidin-3-yl propionate,
5	(3R,5R)-1-(4-chlorophenylcarbamoyl)-5-[4-(3-oxomorpholin-4-
	yl)phenylcarbamoyl]pyrrolidin-3-yl acetate,
	4-N-[(4-chlorophenyl)]-5-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
	1,3-dioxolane-4,5-dicarboxamide,
10	4-N-[(4-chlorophenyl)]-5-N-{[3-methyl-4-(3-oxomorpholin-4-yl)-
	phenyl]}-1,3-dioxolane-4,5-dicarboxamide,
	4-N-[(4-chlorophenyl)]-5-N-{[4-(2-oxo-2H-pyridin-1-yl)phenyl]}-
	1,3-dioxolane-4,5-dicarboxamide,
15	4-N-[(4-chlorophenyl)]-5-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
	1,3-dioxolane-2,2-dimethyl-4,5-dicarboxamide,
	4-N-[(4-chlorophenyl)]-5-N-{[3-methyl-4-(3-oxomorpholin-4-yl)-
	phenyl]}-1,3-dioxolane-2,2-dimethyl-4,5-dicarboxamide,
00	4-N-[(4-chlorophenyl)]-5-N-{[4-(2-oxo-1 <i>H</i> -pyridin-1-yl)phenyl]}-
20	1,3-dioxolane-2,2-dimethyl-4,5-dicarboxamide,
	1-N-[4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-1-
	BOC-piperazine-1,2-dicarboxamide,
	1-N-[4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
25	piperazine-1,2-dicarboxamide,
	1-N-[4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-1,3-
	oxazinane-3,4-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
30	(2R,4S)-4-ethynyl-4-hydroxypyrrolidine-1,2-dicarboxamide,
	6-N-[(4-chlorophenyl)]-7-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-4-
	oxa-6-azaspiro[2.4]heptane-6,7-dicarboxamide,
35	1-N-[(6-chloropyridin-3-yl)]-2-N-{[4-(2-oxo-2 <i>H</i> -pyridin-1-yl)-
	phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
	1-N-[(6-chloropyridin-3-yl)]-2-N-{[4-(2-oxo-2H-pyrazin-1-yl)-
	phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

	1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)-
	phenyl]}-(2R,4S)-4-acetaminopyrrolidine-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
	(2R,4S)-4-butylsulfonylaminopyrrolidine-1,2-dicarboxamide,
5	1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
	(R)-4-oxopyrrolidine-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)-
	phenyl]}-(2R,4S)-4-aminopyrrolidine-1,2-dicarboxamide,
10	1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)-
	phenyl]}-(S)-pyrrolidine-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)-
•	phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
15	N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[2-(4-chloro-
.0	phenyl)acetyl]-4-hydroxypyrrolidine-2-carboxamide,
	N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-(4-chlorobenzoyl)-
•	4-hydroxypyrrolidine-2-carboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)-
20	phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-2 <i>H</i> -pyridin-1-yl)phenyl]}-
	(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)-
25	phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-2 <i>H</i> -pyrazin-1-yl)phenyl]}-
30	(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
	(2R,4S)-4-(2-methylpropanoylamino)pyrrolidine-1,2-dicarboxamide,
	N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-(1-1 <i>H</i> -indol-3-yl-
	methanoyl)-4-hydroxypyrrolidine-2-carboxamide,
	N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-(1-1H-indol-6-yl-
0.5	methanoyl)-4-hydroxypyrrolidine-2-carboxamide,
35	·

1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide, 1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-1*H*-pyridin-1-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide, 5 1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide, 1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-1*H*-pyridin-1-yl)phenyl]}-(2R,4S)-4-ethynyl-4-hydroxypyrrolidine-1,2-dicarboxamide, 10 1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-2*H*-pyrazin-1-yl)phenyl]}-(2R,4S)-4-ethynyl-4-hydroxypyrrolidine-1,2-dicarboxamide, $1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-2H-pyridin-1-yl)phenyl]}-$ 4,4-difluoro-(R)-pyrrolidine-1,2-dicarboxamide, 1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(2-oxo-2*H*-pyridin-1-yl)-15 phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide, 1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(2-oxo-2*H*-pyridin-1-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide, 1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(2-oxo-2*H*-pyridin-1-yl)-20 phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, 2-N-[(4-chlorophenyl)]-1-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide, 2-N-[(4-chlorophenyl)]-1-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(S)-25 pyrrolidine-1,2-dicarboxamide, 1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-3-methoxy-2*H*-pyridin-1yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, 1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-3-methoxy-2*H*-pyridin-1yl)phenyl]]-(R)-pyrrolidine-1,2-dicarboxamide, 30 N-(4-chlorophenyl)-(R)-1-{2-[4-(3-oxomorpholin-4-yl)phenyl]acetyl}pyrrolidine-2-carboxamide, N-(4-chlorophenyl)-(S)-1-{2-[4-(3-oxomorpholin-4-yl)phenyl]acetyl}pyrrolidine-2-carboxamide, 35

	N-(4-chlorophenyl)-(2R,4R)-1-{2-[4-(3-oxomorpholin-4-yl)-
	phenyl]acetyl}-4-methoxypyrrolidine-2-carboxamide,
	N-(4-chlorophenyl)-(2R,4S)-1-{2-[4-(3-oxomorpholin-4-yl)-
_	phenyl]acetyl}-4-methoxypyrrolidine-2-carboxamide,
5	N-(4-chlorophenyl)-(2S,4R)-1-{2-[4-(3-oxomorpholin-4-yl)-
	phenyl]acetyl}-4-methoxypyrrolidine-2-carboxamide,
	N-(4-chlorophenyl)-(S)-1-{2-[4-(2-oxo-1H-pyridin-1-yl)phenyl]-
	acetyl}pyrrolidine-2-carboxamide,
10	N-(4-chlorophenyl)-(S)-1-{2-[4-(2-oxopyrrolidin-1-yl)phenyl]-
	acetyl}pyrrolidine-2-carboxamide,
٠.	N-(4-chlorophenyl)-(R)-1-{2-[4-(2-oxopyrrolidin-1-yl)phenyl]-
	acetyl}pyrrolidine-2-carboxamide,
15	N-(4-chlorophenyl)-(R)-1-[4-(2-oxopiperidin-1-yl)benzoyl]pyr-
	rolidine-2-carboxamide,
	N-(4-chlorophenyl)-(R)-1-[4-(2-oxopiperidin-1-yl)phenyloxy-
•	carbonyl]pyrrolidine-2-carboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-2 <i>H</i> -pyrazin-1-yl)phenyl]}
20	(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[3-fluoro-4-(3-oxomorpholin-4-yl)-
	phenyl]}-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
25	(2R,4R)-4-(prop-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
	(2R,4R)-4-(but-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
30	(2R,4R)-4-(2,3-dihydroxypropoxy)pyrrolidine-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
	(2R,4R)-4-(2-hydroxy-3-pyrrolidin-1-ylpropoxy)pyrrolidine-1,2-
	dicarboxamide,
35	1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
33	(2R,4R)-4-(2-oxooxazolidin-5-ylmethoxy)pyrrolidine-1,2-dicarbox-
	amide,

	1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
	(2R,4R)-4-(3-amino-2-hydroxypropoxy)pyrrolidine-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-1 <i>H</i> -pyrazin-1-yl)phenyl]}-
_	(R)-2,5-dihydropyrrole-1,2-dicarboxamide,
5	1-N-[(4-chlorophenyl)]-2-N-{[4-(2-oxo-1 <i>H</i> -pyridin-1-yl)phenyl]}-
	(R)-2,5-dihydropyrrole-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[3-fluoro-4-(3-oxomorpholin-4-yl)-
	phenyl]}-(R)-2,5-dihydropyrrole-1,2-dicarboxamide,
10	1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)-
	phenyl]}-(R)-2,5-dihydropyrrole-1,2-dicarboxamide,
•	1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
	(2S,3S)-3-hydroxypyrrolidine-1,2-dicarboxamide,
15	1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
	(2S,4S)-4-hydroxypyrrolidine-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[2-methoxycarbonyl-4-(3-oxomor-
	pholin-4-yl)phenyl]}-(2R,4R)-3-hydroxypyrrolidine-1,2-dicarboxamide,
00	1-N-[(4-chlorophenyl)]-2-N-{[2-carboxy-4-(3-oxomorpholin-4-yl)-
20	phenyl]}-(2R,4R)-3-hydroxypyrrolidine-1,2-dicarboxamide,
•	1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
	(2R,3S,4R)-3,4-dihydroxypyrrolidine-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)-
25	phenyl]}-(2R,4R)-4-allyloxypyrrolidine-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)-
	phenyl]}-(2R,4R)-4-(prop-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)-
30	phenyl]}-(2R,4S)-4-(prop-2-ynyloxy)pyrrolidine-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
	(2R,4R)-4-(methoxycarbonylmethoxy)pyrrolidine-1,2-dicarboxamide,
35	1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
	(2R,4R)-4-(carboxymethoxy)pyrrolidine-1,2-dicarboxamide,
	1-N-[(4-bromophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)-
	phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-dicarboxamide,

	1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-(3-oxomorpholin-4-yl)-
	•
	phenyl]}-(2R,4R)-4-(2,3-dihydroxypropoxy)pyrrolidine-1,2-dicarbox-
•	amide,
5	1-N-[(4-chlorophenyl)]-2-N-{N-methoxycarbonylmethyl-N'-[4-(3-
5	oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-methoxypyrrolidine-1,2-
	dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)cyclohexan-
	1-yl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
10	1-N-[(4-chlorophenyl)]-2-N-{[4-(2-iminopyrrolidin-1-yl)phenyl]}-
	(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, ESI 442;
	1-N-[(4-chlorophenyl)]-2-N-{[3-methyl-4-(2-iminopyrrolidin-1-yl)-
	phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, ESI 456;
15	1-N-[(4-chlorophenyl)]-2-N-[4-{2-[(E)-cyanimino]imidazolidin-1-
	yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, ESI 468;
	1-N-[(4-chlorophenyl)]-2-N-{[4-(2-imino-5-methylthiazol-3-yl)-
	phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, ESI 473;
	1-N-[(4-chlorophenyl)]-2-N-{[2-aminocarbonyl-4-(3-oxomorpho-
20	lin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, ESI
	502;
	1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
£	(2R,4R)-4-hydroxy-2-methylpyrrolidine-1,2-dicarboxamide,
25	N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chloro-
	thiophen-2-yl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,
	N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-thiophen-3-
	ylacryloyl]-4-hydroxypyrrolidine-2-carboxamide,
20	N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(2E,4E)-5-phenyl-
30	penta-2,4-dienyloyl]-4-hydroxypyrrolidine-2-carboxamide,
	N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-methyl-
	furan-2-yl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,
	N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-thiophen-2-
35	ylacryloyl]-4-hydroxypyrrolidine-2-carboxamide,
	yldorylogig i ligaroxypyrronamic = cana criminaly

	N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-
	chlorothiophen-2-yl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,
	N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-
	chlorothiophen-2-yl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,
5	N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-chloro-
	phenyl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,
	N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(3,4-
	dichlorophenyl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,
10	N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-chloro-
•	phenyl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,
	N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(3,4-
	dichlorophenyl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,
15	N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-1H-imidazol-14-(B)-14-(B)-(B)-14-(B)-14-(B)-(B)-14-(B)-(B)-(B)-(B)-(B)-(B)-(B)-(B)-(B)-(B)
	4-ylacryloyl]-4-hydroxypyrrolidine-2-carboxamide,
	N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chloro-
•	thiophen-2-yl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,
00	N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chloro-
20	furan-2-yl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,
	N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chloro-
	furan-2-yl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,
	N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-chloro-
25	phenyl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,
	N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(3,4-
	dichlorophenyl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,
	N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chloro-
30	furan-2-yl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,
	N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-chloro-
	thiophen-2-yl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,
35	N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-
	chlorophenyl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,
	N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-
	(3,4-dichlorophenyl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,

	N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-
	chlorofuran-2-yl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,
	N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-
	chlorofuran-2-yl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,
5	N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-
	chlorophenyl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,
	N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-
•	(3,4-dichlorophenyl)acryloyl]-4-methoxypyrrolidine-2-carboxamide,
10	N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-
	chlorophenyl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,
	N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-
	(3,4-dichlorophenyl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,
15	N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-
	chlorofuran-2-yl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,
	N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-
	chlorothiophen-2-yl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,
00	N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-1H-imidazol-2]
20	4-ylacryloyl]-4-ethoxypyrrolidine-2-carboxamide,
`	N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-1 <i>H</i> -
	imidazol-4-ylacryloyl]-4-hydroxypyrrolidine-2-carboxamide,
	N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-1H-1]
25	imidazol-4-ylacryloyl]-4-methoxypyrrolidine-2-carboxamide,
	N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-1 <i>H</i> -
	imidazol-4-ylacryloyl]-4-ethoxypyrrolidine-2-carboxamide,
	N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-
30	pyridin-3-ylacryloyl]-4-hydroxypyrrolidine-2-carboxamide,
	N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-3-
	ylacryloyl]-4-ethoxypyrrolidine-2-carboxamide,
	N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-
35	pyridin-3-ylacryloyl]-4-methoxypyrrolidine-2-carboxamide,
30	

•	
	N-[2-fluoro-4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-
	pyridin-3-ylacryloyl]-4-ethoxypyrrolidine-2-carboxamide,
	N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-3-
5	ylacryloyl]-4-hydroxypyrrolidine-2-carboxamide,
	N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-3-
	ylacryloyl]-4-methoxypyrrolidine-2-carboxamide,
	N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-4-
	ylacryloyl]-4-hydroxypyrrolidine-2-carboxamide,
10	N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-pyridin-4-
•	ylacryloyl]-4-ethoxypyrrolidine-2-carboxamide,
	N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-1H-imidazol-
	4-ylacryloyl]-4-methoxypyrrolidine-2-carboxamide,
15	N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-bromo-
	thiophen-2-yl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,
٠.	N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(4-bromo-
	thiophen-2-yl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,
00	N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-bromo-
20	thiophen-2-yl)acryloyl]-4-hydroxypyrrolidine-2-carboxamide,
	N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-1-[(E)-3-(5-bromo-
	thiophen-2-yl)acryloyl]-4-ethoxypyrrolidine-2-carboxamide,
	N-(4-chlorophenyl)-(R)-1-[4-(2-oxopiperidin-1-yl)benzoyl]pyr-
25	rolidine-2-carboxamide,
•	N-(4-chlorophenyl)-(S)-1-[4-(2-oxopiperidin-1-yl)benzoyl]pyr-
	rolidine-2-carboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[4-(5-oxo-1,4-oxazepan-4-yl)-
30	phenyl]}-(R)-pyrrolidine-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[4-(5-oxo-1,4-oxazepan-4-yl)-
	phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
	1-N-[(4-chlorophenyl)]-2-N-{[4-((S)-2-methyl-3-oxomorpholin-4-
	yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
35	1-N-[(4-chlorophenyl)]-2-N-{[4-((S)-2-methyl-3-oxomorpholin-4-
	yl)phenyl]}-(2R)-pyrrolidine-1,2-dicarboxamide,

		1-N-[(4-chlorophenyl)]-2-N-{[4-((R)-2-methyl-3-oxomorpholin-4-
		yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
		1-N-[(4-chlorophenyl)]-2-N-{[4-((R)-2-methyl-3-oxomorpholin-4-
5		yl)phenyl]}-(2R)-pyrrolidine-1,2-dicarboxamide,
		1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)-2-phenoxy-
		phenyl]}-(2R)-pyrrolidine-1,2-dicarboxamide,
		1-N-[(4-chlorophenyl)]-2-N-{[2-fluoro-4-((R)-2-methyl-3-oxo-
		morpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarbox-
10		amide,
		1-N-[(4-chlorophenyl)]-3-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
	-	piperidine-1,3-dicarboxamide,
15		1-N-[(4-chlorophenyl)]-3-N-{[3-methyl-4-(3-oxomorpholin-4-yl)-
		phenyl]}piperidine-1,3-dicarboxamide,
		1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
		(2R,4R)-4-(2-methoxyethoxy)pyrrolidine-1,2-dicarboxamide,
		1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxo-1,4-oxazepan-4-yl)-
00		phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
20	•	1-N-[(4-chlorophenyl)]-2-N-{[2-methyl-4-(3-oxomorpholin-4-yl)-
		phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
		1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-
	. :	(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
25		1-N-[(4-chlorophenyl)]-2-N-{[2-(3-oxomorpholin-4-yl)phenyl]}-
		(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,
		and pharmaceutically usable derivatives, solvates, salts and stereo-
30		isomers thereof, including mixtures thereof in all ratios.
	24.	Pyrrolidinecarboxylic acid derivatives selected from the group consist-

ing of

1-N-[(4-chlorophenyl)]-2-N-[(1'-methyl-[1,4']bipiperidinyl-4-yl)]- (2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide,

25.

sisting of

1-N-[(4-chlorophenyl)]-2-N-[(3,4,5,6-tetrahydro-2H-1,4'-bipyridinyl-4-yl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, 1-N-[(4-chlorophenyl)]-2-N-[(3,4,5,6-tetrahydro-2H-1,4'-bipyridinyl-4-yl)-(2R,4R)-4-ethoxypyrrolidine-1,2-dicarboxamide, 5 N-(4-chlorophenyl)-(2R,4R)-4-hydroxy-2-(4-pyridin-4-ylpiperazine-1-carbonyl)pyrrolidine-1-carboxamide, N-(4-chlorophenyl)-(2R,4R)-4-hydroxy-2-[4-(2-methoxyphenyl)piperazine-1-carbonyl]pyrrolidine-1-carboxamide, N-(4-chlorophenyl)-(2R,4R)-2-[4-(4-fluorophenyl)piperazine-1-10 carbonyl]-4-hydroxypyrrolidine-1-carboxamide, N-(4-chlorophenyl)-(2R,4R)-4-hydroxy-2-[4-hydroxy-4-(4methoxyphenyl)piperidine-1-carbonyl]pyrrolidine-1-carboxamide, N-(4-chlorophenyl)-(2R,4R)-4-hydroxy-2-(4-pyridin-2-yl-15 piperazine-1-carbonyl)pyrrolidine-1-carboxamide, N-(4-chlorophenyl)-(2R,4R)-2-[4-(4-ethylpiperazin-1-yl)piperidine-1-carbonyl]-4-hydroxypyrrolidine-1-carboxamide, N-(4-chlorophenyl)-(2R,4R)-2-[4-(4,6-dimethylpyrimidin-2-yl)-20 piperazine-1-carbonyl]-4-hydroxypyrrolidine-1-carboxamide, N-(4-chlorophenyl)-(2R,4R)-4-hydroxy-2-[4-(1-methylpiperidin-4yl)piperazine-1-carbonyl]pyrrolidine-1-carboxamide, 1-N-[(4-chlorophenyl)]-2-N-{[2-(2-dimethylaminoethoxy)-4-morpholin-4-ylphenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, 25 1-N-[(4-chlorophenyl)]-2-N-[(2-ethoxy-4-morpholin-4-ylphenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, 1-N-[(4-chlorophenyl)]-2-N-[(4-morpholin-4-yl-2-propoxyphenyl)]-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide, 30 and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios. 35 Cyclopentanecarboxylic acid derivatives selected from the group con-

15

20

25

30

35

N-[4-(3-oxomorpholin-4-yl)phenyl]-(rac)-2-[3-(4-chlorophenyl)-ureido]cyclopentanecarboxamide,

N-[3-methyl-4-(3-oxomorpholin-4-yl)phenyl]-(rac)-2-[3-(4-chlorophenyl)ureido]cyclopentanecarboxamide,

and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios.

- 26. Process for the preparation of compounds of the formula I according
 - to Claims 1-23 and pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, characterised in that
 - a) for the preparation of compounds of the formula I in which
 - W is N and
 - G is NH,

a compound of the formula II

$$R^1 \stackrel{\mathsf{E}}{\underset{\mathsf{H}}{\bigvee}} X \stackrel{\mathsf{Y}}{\underset{\mathsf{T}}{\bigvee}} T$$

in which

 R^1 , R^2 , E, X, Y and T are as defined in Claim 1, and W is N,

is reacted with a compound of the formula III

in which

D is as defined in Claim 1,

or

5

b) for the preparation of compounds of the formula I in which $X \qquad \text{is -}[C(R^4)_2]_n CONR^3[C(R^4)_2]_{n^-},$

a compound of the formula IV

10

$$HNR^{3}$$
- $[C(R^{4})_{2}]_{n}$ -Y-T

IV

in which R3, n, Y and T are as defined in Claim 1,

15

is reacted with a compound of the formula V

20

$$R^1 \xrightarrow{E} R^2$$
 $[C(R^4)_2]_n$ -CO-L
 $D-G$

in which

25

L is CI, Br, I or a free or reactively functionally modified OH group, and

R¹, R², R⁴, D, E, G, W and n are as defined in Claim 1,

30

or

- c) for the preparation of compounds of the formula I in which W is N,
- a compound of the formula II

$$R^{1} \xrightarrow{E} X^{2} X - Y - T$$

$$\downarrow \qquad \qquad \parallel$$

$$H$$

in which

 R^1 , R^2 , E, X, Y and T are as defined in Claim 1, and W is N,

10

is reacted with a compound of the formula VI

VI

15

20

in which D and G are as defined in Claim 1, and
L is Cl, Br, I or a free or reactively functionally modified OH group,

and/or

a base or acid of the formula I is converted into one of its salts.

- 27. Compounds of the formula I according to one or more of Claims 1 to 23 and the compounds of Claims 24 and 25 as inhibitors of coagulation factor Xa.
- 28. Compounds of the formula I according to one or more of Claims 1 to 23 and the compounds of Claims 24 and 25 as inhibitors of coagulation factor VIIa.

30

35

25

29. Medicament comprising at least one compound of the formula I according to one or more of Claims 1 to 23 or a compound of Claims 24 and 25 and/or pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios, and, if desired, excipients and/or adjuvants.

25

- 30. Medicament comprising at least one compound of the formula I according to one or more of Claims 1 to 23 or a compound of Claims 24 and 25 and/or pharmaceutically usable derivatives, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further medicament active ingredient.
- 31. Use of compounds according to one or more of Claims 1 to 23 or the compounds of Claims 24 and 25 and/or physiologically acceptable salts, salts and solvates thereof for the preparation of a medicament for the treatment of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases.
 - 32. Set (kit) consisting of separate packs of
- (a) an effective amount of a compound of the formula I according to one or more of Claims 1 to 23 or a compound of Claims 24 and 25 and/or pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios, and
 - (b) an effective amount of a further medicament active ingredient.
- 33. Use of compounds of the formula I according to one or more of
 Claims 1 to 23 or of compounds of Claims 24 and 25 and/or pharmaceutically usable derivatives, solvates, salts and stereoisomers
 thereof, including mixtures thereof in all ratios, for the preparation of
 a medicament for the treatment of thromboses, myocardial infarction,
 arteriosclerosis, inflammation, apoplexy, angina pectoris, restenosis
 after angioplasty, claudicatio intermittens, migraine, tumours, tumour
 diseases and/or tumour metastases,


in combination with at least one further medicament active ingredient.

34. Intermediate compounds of the formula I-1

5

15

20



10 in which

D is phenyl, pyridyl, thienyl, furyl or imidazolyl, each of which is monosubstituted or disubstituted by Hal,

R¹ is H, OH, OA, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms or ethynyl,

R² is H, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

E is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-3,4-

or 3,5-diyl,

G is $(CH_2)_n$, $(CH_2)_nNH_-$, -CH=CH- or -CH=CH-CH=CH-,

X is COOH,

A is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

Hal is F, Cl, Br or l, n is 0, 1 or 2,

and isomers and salts thereof.

30 35. Compounds according to Claim 34, selected from the group consisting of

3-(4-chlorophenylcarbamoyl)oxazolidine-4-carboxylic acid,

3-(5-chlorothiophene-2-carbonyl)oxazolidine-5-carboxylic acid,

35 and isomers and salts thereof.

- 36. Intermediate compounds selected from the group consisting of (2R,4S)-BOC-4-ethynyl-4-hydroxy-pyrrolidine-2-carboxylic acid, (2R,4R)-BOC-4-ethynyl-4-hydroxy-pyrrolidine-2-carboxylic acid, alkyl (2R,4S)-BOC-4-ethynyl-4-hydroxypyrrolidine-2-carboxylate, alkyl (2R,4R)-BOC-4-ethynyl-4-hydroxypyrrolidine-2-carboxylate, where alkyl has 1, 2, 3, 4, 5 or 6 carbon atoms, and isomers and salts thereof.
- 10 37. Intermediate compounds of the formula I-2

$$R^{1} \stackrel{\mathsf{E}}{\underbrace{\hspace{1cm}}} X^{2} \\ V \\ V \\ \mathsf{I}$$

in which

20

is H, =O, COOR³, OH, OA, NH₂, alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, N₃, ethynyl, vinyl, allyloxy, NHCOA, NHSO₂A, OCH₂COOA or OCH₂COOH,

R² is H, OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

25 R¹ and R² together are alternatively a spirocyclically bonded 3- to 6-membered carbocyclic ring,

 R^3 is H or A,

is pyrrolidine-1,2-diyl, piperidine-1,2-diyl, oxazolidine-

3,4- or 3,5-diyl,

X is CONH,

is 1,3- or 1,4-phenylene which is unsubstituted or monosubstituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F, T is piperidin-1-yl, pyrrolidin-1-yl, 1*H*-pyridin-1-yl, morpholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, 2*H*-pyridazin-2-yl, pyrazin-1-yl, azepan-1-yl or 2-azabicyclo[2.2.2]octan-2-yl, each of which is monosubstituted or disubstituted by carbonyl oxygen,

A is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

Hal is F, Cl, Br or l,

n is 0, 1 or 2,

and isomers and salts thereof.

38. Compounds according to Claim 37 of the formula I-2a

15 I-2a 20 in which is H. =O. COOR³, OH, OA, NH₂, alkyl having 1, 2, 3, 4, R^1 5 or 6 carbon atoms, N₃, ethynyl, vinyl, allyloxy, NHCOA, NHSO₂A, OCH₂COOA or OCH₂COOH, R^2 is H. OH, OA or alkyl having 1, 2, 3, 4, 5 or 6 carbon 25 atoms, R^3 is H or A, is pyrrolidine-1,2-diyl, 30 Χ is CONH. is 1,3- or 1,4-phenylene which is unsubstituted or monosubstituted or disubstituted by methyl, trifluoromethyl, ethyl, propyl, Cl or F, 35

1

20

25

	Т	is piperidin-1-yl, pyrrolidin-1-yl, 1H-pyridin-1-yl, mor-
		pholin-4-yl, piperazin-1-yl, 1,3-oxazolidin-3-yl, 2 <i>H</i> -pyri-
		dazin-2-yl, pyrazin-1-yl, azepan-1-yl or 2-azabicyclo-
;		[2.2.2]octan-2-yl, each of which is monosubstituted or
		disubstituted by carbonyl oxygen,
	Α	is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,
	Hal	is F, Cl, Br or I,
	n	is 0, 1 or 2,
10	and isomers	s and salts thereof.

39. Compounds according to Claim 38, selected from the group consisting of

N-[4-(3-oxomorpholin-4-yl)phenyl]-(S)-pyrrolidine-2-carboxamide,
N-[4-(3-oxomorpholin-4-yl)phenyl]-(R)-pyrrolidine-2-carboxamide,
N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-4-hydroxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(R)-4,4-dimethoxypyrrolidine-2-carboxamide,

N-[4-(3-oxomorpholin-4-yl)phenyl]-(2R,4R)-4-methoxypyrrolidine-2-carboxamide, and isomers and salts thereof.

40. Medicament according to Claim 30, comprising 1-N-[(4-chloro-phenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxy-pyrrolidine-1,2-dicarboxamide and/or pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios, and aspirin.

41. Use according to Claim 33, comprising 1-N-[(4-chlorophenyl)]-2-N-{[4-(3-oxomorpholin-4-yl)phenyl]}-(2R,4R)-4-hydroxypyrrolidine-1,2-dicarboxamide and/or pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, including mixtures thereof in all ratios, in combination with aspirin.